The Biosynthesis, Fate and Pharmacological Properties of Endocannabinoids 183Price TJ, Patwardhan A, Akopian AN, Hargreaves KM, Flores CM (2004) Modulation of
trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anan-
damide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. Br J Pharma-
col 141:1118–1130
Puffenbarger RA, Kapulin O, Howell JM, Deutsch DG (2001) Characterization of the 5’-
sequence of the mouse fatty acid amide hydrolase. Neurosci Lett 314:21–24
Ralevic V, Duncan M, Millns P, Smart D, Wright J, Kendall D (2004) Noladin ether, a putative
endocannabinoid, attenuates sensory neurotransmission in the rat isolated mesenteric
arterial bed via a non CB1/CB2 Gi/o linked receptor. Br J Pharmacol 142:509–518
Randall MD, Harris D, Kendall DA, Ralevic V (2002) Cardiovascular effects of cannabinoids.
Pharmacol Ther 95:191–202
RavinetTrillouC,ArnoneM,DelgorgeC,GonalonsN,KeaneP,MaffrandJP,SoubrieP(2003)
Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice.
Am J Physiol Regul Integr Comp Physiol 284:R345–R353
Ravinet Trillou C, Delgorge C, Menet C, Arnone M, Soubrie P (2004) CB1 cannabinoid
receptor knockout in mice leads to leanness, resistance to diet-induced obesity and
enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28:640–648
Ronesi J, Gerdeman GL, Lovinger DM (2004) Disruption of endocannabinoid release and
striatal long-term depression by postsynaptic blockade of endocannabinoid membrane
transport. J Neurosci 24:1673–1679
Ross RA (2003) Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140:790–801
Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, Pertwee RG
(2001) Structure-activity relationship for the endogenous cannabinoid, anandamide,
and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.
Br J Pharmacol 132:631–640
Ruiz-Llorente L, Ortega-Gutiérrez S, Viso A, Sánchez MG, Sánchez AM, Fernández C, Ramos
JA, Hillard C, Lasunción MA, López-Rodríguez ML, Díaz-Laviada I (2004) Characteri-
zation of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis
of new transporter inhibitors as tools for this study. Br J Pharmacol 141:457–467
Sagan S, Venance L, Torrens Y, Cordier J, Glowinski J, Giaume C (1999) Anandamide
and WIN 55212-2 inhibit cyclic AMP formation through G-protein-coupled receptors
distinct from CB1 cannabinoid receptors in cultured astrocytes. Eur J Neurosci 11:691–
699
Sanchez C, de Ceballos ML, del Pulgar TG, Rueda D, Corbacho C, Velasco G, Galve-Roperh
I, Huffman JW, Ramon y Cajal S, Guzman M (2001) Inhibition of glioma growth in vivo
by selective activation of the CB(2) cannabinoid receptor. Cancer Res 61:5784–5789
Schmid HH, Schmid PC, Natarajan V (1990) N-acylated glycerophospholipids and their
derivatives. Prog Lipid Res 29:1–43
Schmid HH, Schmid PC, Natarajan V (1996) The N-acylation-phosphodiesterase pathway
and cell signalling. Chem Phys Lipids 80:133–142
SchmidHH,SchmidPC,BerdyshevEV(2002a)Cellsignalingbyendocannabinoidsandtheir
congeners: questions of selectivity and other challenges. Chem Phys Lipids 121:111–134
Schmid PC, Wold LE, Krebsbach RJ, Berdyshev EV, Schmid HH (2002b) Anandamide and
other N-acylethanolamines in human tumors. Lipids 37:907–912
Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM (2001) Striatal cannabi-
noid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of
Parkinson’s disease. Exp Neurol 169:400–406
SmartD, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis
JB (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid
receptor (hVR1). Br J Pharmacol 129:227–230
Stella N, Piomelli D (2001) Receptor-dependent formation of endogenous cannabinoids in
cortical neurons. Eur J Pharmacol 425:189–196
Stella N, Schweitzer P, Piomelli D (1997) A second endogenous cannabinoid that modulates
long-term potentiation. Nature 388:773–778